消化道恶性肿瘤患者血清可溶性肿瘤坏死因子受体-Ⅰ的检测及其临床评价  

Detection and its clinical significance of serum soluble tumor necrosis factorreceptor-I in patients with malignant carcinoma of digestive system

作　　者：王瑞华[1] 杨存葆[1] 刘志强[1] 陈书恩[1] 徐培仁 程冠昌[1] 杜盛宏 

机构地区：[1]开封医专附属淮河医院,开封475001

出　　处：《开封医专学报》2000年第1期3-5,共3页Journal of Henan University(Medical Science)

摘　　要：目的 :了解可溶性肿瘤坏死因子受体 -Ⅰ (sTNFR -Ⅰ )在消化道恶性肿瘤患者中的临床意义。方法 :应用双抗体夹心ELISA法 ,对 37例食管癌、4 1例胃癌、30例大肠癌患者血清sTNFR -Ⅰ水平进行了检测。结果 :三组肿瘤患者血清sTNFR -Ⅰ水平显著高于对照组 ,且随肿瘤临床病理分期增加而增高 ,有转移者 ,显著高于无转移者。手术切除肿瘤后sTNFR -Ⅰ水平下降 ,肿瘤复发时 ,sTNFR -Ⅰ水平上升。结论 :检测血清sTNFR -Ⅰ水平有助于消化道恶性肿瘤患者的诊断及预后判断。Objective To define the clinical significance of serum soluble tumor necrosis factor receptor-I (sTNR-I) in patients with malignant carcinoma of digestive system . Method Serum levels of sTNFT-I using EKISA technique serum in 37 patients with esophageal carcinoma (EC),41 patients with gas carcinoma(GC), 30 patients with colorectal carinoma(CC)are measured. Results The levels of sTNFR-I in patients with EC, GC and CC were significantly higher than that of control group. The more clinicopathologic stage of malignant tumor , the higher serum levels of sTNFR-I. It was higher in patients with metastasis than those without metastasis. levels of sTNFR-I were significantly lower in patients with malignant tumor after surgical removal of tumor. A rise again in serum sTNFR-I level were found to correlate with tumor recurrence. Conclusion This study suggests that malignangt of serum sTNFR-I is useful for the diagnosis and prognosis of malignant carcinoma of digestive system.

关 键 词：消化道恶性肿瘤 STNFR-I 双抗体夹心ELISA 

分 类 号：R735.04[医药卫生—肿瘤]